Global Food Allergy Treatment Market Size To Worth USD 13.76 Billion By 2033 | CAGR of 9.27%
June 28, 2024 22:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 28, 2024 (GLOBE NEWSWIRE) -- The Global Food Allergy Treatment Market Size is to Grow from USD 5.67 Billion in 2023 to USD 13.76 Billion by 2033, at a Compound Annual...
Global Immunomodulator Market Projected to Nearly Double, Reaching $477.55 Billion by 2034 - Evolution of Immunomodulatory Treatments for Cancer Creating Lucrative Opportunities for Oncology Applications
June 27, 2024 09:43 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Global Immunomodulator Market" report has been added to ResearchAndMarkets.com's offering.In a significant development for the healthcare industry,...
Global Cancer Immunotherapy Market Report 2024, with Revenue Forecasts to 2034 for Five Regional and 25 Key National Markets
June 27, 2024 07:02 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Cancer Immunotherapy Market is...
$7 Bn House Dust Mite Allergy Global Market Opportunities and Strategies to 2033 - Innovative AI-Powered Allergy Testing Revolutionizes Market Dynamics
June 26, 2024 06:22 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "House Dust Mite Allergy Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global...
Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials
June 20, 2024 06:59 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Global KRAS Inhibitors Market & Clinical Trials Future Outlook 2030" report has been added to ResearchAndMarkets.com's offering. With the...
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
June 18, 2024 15:17 ET
|
Tevogen Bio Inc
Untapped potential and development of a new class of T Cell therapies for large patient populations. Overcoming CAR-T challenges.
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by...
Tevogen Bio Set to Join Russell 3000® Index
June 12, 2024 15:45 ET
|
Tevogen Bio Inc
Tevogen Bio is set to join the Russell 3000® Index effective at the open of US equity markets on Monday, July 1.
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
June 11, 2024 15:30 ET
|
Tevogen Bio Inc
Agreement for Up to $50 Million in Financing. Includes $36 million line of credit and potential $14 million private placement.
Trispecific Antibodies Set to Transform the Future of Immunotherapy: Trispecific Antibodies Clinical Trials Insight by Company, Country, Indication & Phase
June 07, 2024 02:59 ET
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global Trispecific Antibodies Clinical Trials & Market Outlook 2024" report has been added to ResearchAndMarkets.com's offering. The blueprint...